May 2006
Volume 47, Issue 13
ARVO Annual Meeting Abstract  |   May 2006
Delivery of Encapsulated Cell Technology (ECT) Device Implants Using a Small Gauge Needle
Author Affiliations & Notes
  • K.A. Kauper
    Neurotech USA, Lincoln, RI
  • P. Stabila
    Neurotech USA, Lincoln, RI
  • J. Mills
    Neurotech USA, Lincoln, RI
  • A. Lee
    Neurotech USA, Lincoln, RI
  • D. Litvak
    Neurotech USA, Lincoln, RI
  • J. Lydon
    Neurotech USA, Lincoln, RI
  • P. Heatherton
    Neurotech USA, Lincoln, RI
  • W. Tao
    Neurotech USA, Lincoln, RI
  • Footnotes
    Commercial Relationships  K.A. Kauper, Neurotech USA, Inc, F; P. Stabila, N eurotech USA, F; J. Mills, Neurotech USA, Inc, F; A. Lee, Neurotech USA, Inc, F; D. Litvak, Neurotech USA, Inc, F; J. Lydon, Neurotech USA, Inc, F; P. Heatherton, Neurotech USA, Inc, F; W. Tao, Neurotech USA, Inc, F.
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science May 2006, Vol.47, 5118. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      K.A. Kauper, P. Stabila, J. Mills, A. Lee, D. Litvak, J. Lydon, P. Heatherton, W. Tao; Delivery of Encapsulated Cell Technology (ECT) Device Implants Using a Small Gauge Needle . Invest. Ophthalmol. Vis. Sci. 2006;47(13):5118.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: : Implantation of an ECT device currently requires a 2.0 mm sclerotomy and three sutures to close the incision site. Development of an ECT device that could be implanted through a small gauge needle would minimize surgical risk.

Methods: : Micro ECT devices have been developed that are 200–fold smaller in overall displacement volume than those currently used in Neurotech clinical trials (0.03 µl compared to 6 µl). Microdevices were encapsulated with cells transfected to produce either ciliary neurotrophic factor (CTNF), interleukin–10 (IL–10) or pigment epithelial derived factor (PEDF). Delivery of micro–devices was tested through a 25–gauge needle with a modified syringe. Devices with conventional anchor loops to facilitate suture anchoring as well as modified anchor geometries using nitinol wire were investigated.

Results: : Microdevices produced 2.0 ± 0.5, 3.0 ± 0.7, and 39 ± 4 ng/device/day of CNTF, IL–10 and PEDF, respectively. Protein secretion from the micro ECT devices was consistent and stable over the course of several months with protein output to device volume levels 10 times greater than the capacity of the current clinical device. Microdevices were injected successfully via a 25–gauge needle and preliminary evaluations of anchoring methods indicate successful placement and constraint of the device.

Conclusions: : Encapsulation using microdevices can provide therapeutic protein levels comparable to the current device configuration used in clinical trial evaluations of ECT. Surgical implant of a microdevice using a 25–gauge needle to inject the devices appear to be feasible and may offer a simpler, less invasive approach to encapsulation cell therapy in the eye.

Keywords: growth factors/growth factor receptors • retina • photoreceptors 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.